查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1813272

DNA编码库市场预测至2032年：材质、工作流程、技术、分销管道、应用、最终用户和地区进行的全球分析

DNA Encoded Library Market Forecasts to 2032 - Global Analysis By Material (DNA Oligonucleotides, Chemical Linkers and Synthetic Building Blocks), Workflow, Technology, Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球 DNA 编码库市场规模预计在 2025 年达到 35 亿美元，到 2032 年将达到 67 亿美元，预测期内的复合年增长率为 9.8%。

DNA编码化合物库是由化学连接到独特DNA序列的小分子组成的集合，这些DNA序列充当条码，能够快速识别具有生物活性的化合物。它们用于药物研发，能够针对目标蛋白对数百万至数十亿种化合物进行高通量筛检。 DNA标籤能够有效率地筛选、扩增和序列测定潜在的候选药物。这项技术融合了化学和分子生物学，简化了早期药物研究，并显着加快了有前景的先导化合物的鑑定。

据世界卫生组织 (WHO) 称，随着製药公司寻求多样化其产品线并发现新化合物以满足未满足的医疗需求，特别是在癌症、神经系统疾病和罕见遗传疾病方面（DECL 在这些方面具有特别的前景），越来越多的药物研发资源被分配给 DECL 等创新药物研发技术。

加大对医药研发的投入

DNA编码化合物库市场的发展得益于不断增加的药物研发投入，旨在加速药物发现。製药公司和研究机构正在投入大量资金用于先进的筛检技术，以有效识别候选药物。 DEL平台能够快速测试数十亿种化合物，从而降低临床前阶段的成本和时间。在慢性病发病率上升和精准医疗需求的推动下，药物研发的扩张持续成为全球市场推广的主要催化剂。

图书馆设计流程的专业知识有限

阻碍DNA编码库市场发展的关键因素是缺乏设计和合成复杂分子库的专业知识。 DEL需要化学、分子生物学和生物资讯学的高级技术能力和专业知识。许多製药公司和学术机构在建立内部能力方面面临挑战，减缓了其应用速度。虽然外包给专业的合约研究组织（CRO）可以部分弥补这一差距，但依赖外部专业知识往往会增加成本并限制扩充性。因此，有限的设计专业知识限制了DEL平台在全球的快速扩张。

生技企业与製药公司的合作

生技公司与大型製药企业建立策略联盟，为强化DNA编码化合物库平台带来了良好的机会。伙伴关係关係可以共享资源、技术专长和化合物库，加速新型治疗分子的辨识。此类合作促进了跨行业创新，并透过分担成本降低了开发平臺的风险。越来越多的生物技术企业利用DEL平台，在製药公司销售能力的支持下共同开发标靶药物。这种协作生态系统增强了创新管道，并在治疗开发领域开闢了丰厚的利润机会。

关于使用基因数据的伦理问题

DNA编码库市场面临着与基因资料在研究中使用相关的伦理问题的潜在威胁。虽然DEL专注于药物研发，但它们通常与基因组资料集交叉，从而引发与隐私和知情同意相关的问题。敏感生物资讯的滥用或未授权存取可能会破坏相关人员之间的信任。此外，各地区严格的资料保护条例也为企业带来了合规挑战。围绕基因数据使用的伦理审查仍然是一个重大障碍，可能会阻碍其长期应用。

COVID-19的影响：

COVID-19疫情改变了药物研发的重点，并加速了DNA编码库在快速治疗药物筛检的应用。 DEL平台实现了针对SARS-CoV-2靶点的高通量化合物筛检，为抗病毒研究做出了贡献。然而，供应链中断暂时影响了合成工作流程和实验室合作。疫情过后，人们重新重视感染疾病的防范，凸显了可扩展药物研发方法的重要性。随着新冠疫情以外的药物研发管线不断扩展，DEL平台已成为支援研发速度和效率的关键工具。

预测期内，DNA寡核苷酸片段预计将达到最大

DNA寡核苷酸领域预计将在预测期内占据最大的市场份额，这得益于其在构建和编码海量分子库中的重要作用。 DNA寡核苷酸如同条码，能够大规模辨识结合交互作用。其在高通量筛检中的多功能性以及在肿瘤学、免疫学和感染疾病研究中日益增长的应用正在推动需求成长。合成技术的不断进步使DNA寡核苷酸更具成本效益，进一步巩固了其在市场中的主导地位。

预测期内，文库设计与合成部分将以最高复合年增长率成长

预计化合物库设计和合成领域将在预测期内实现最高成长率，这得益于针对特定治疗标靶客製化化合物库的需求不断增长。先进的计算工具和人工智慧驱动的方法使大型化合物库的精确设计成为可能。製药公司正在寻求高品质且多样化的化合物组合，以改善化合物的识别。合约研究组织 (CRO) 与製药公司之间合作的不断扩大，正在加速对复杂化合物库设计工作流程的投资，使该领域成为市场上成长最快的领域。

占比最高的地区：

预计亚太地区将在预测期内占据最大的市场份额，这得益于不断扩大的医药研发基地、政府对生物技术的投资增加以及成本效益更高的临床试验。中国、印度和日本等国家正积极采用DEL平台来加速药物研发。强大的产学合作、高水准研究人员的资源以及对平价疗法日益增长的需求，正在推动该地区的成长。凭藉规模成长、成本优势和技术创新的不断提升，该地区已在DEL市场确立了主导地位。

复合年增长率最高的地区：

预计北美在预测期内将呈现最高的复合年增长率，这得益于其强大的製药基础设施、先进的技术应用以及雄厚的研究资金。在大型製药企业、生技新兴企业和学术机构的支持下，美国仍是DEL创新的重要枢纽。与合约研究组织（CRO）的持续合作以及对精准医疗的持续投资进一步支持了成长。强大的监管支持和成熟的医疗保健生态系统使北美成为成长最快的地区，为快速扩张创造了肥沃的土壤。

免费客製化服务：

此报告的订阅者可以使用以下免费自订选项之一：

  • 公司简介
    • 全面分析其他市场参与者（最多 3 家公司）
    • 主要企业的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球DNA编码图书馆市场（按材质）

  • DNA寡核苷酸
  • 化学连接体
  • 合成块

6. 全球 DNA 编码图书馆市场（依工作流程）

  • 文库筛检与分析
  • 图书馆设计与合成

7. 全球DNA编码图书馆市场（依技术）

  • DNA引导合成（DDS）
  • DNA记录合成
  • DNA模板合成
  • DNA标记亲和性选择
  • 其他技术

8. 全球DNA编码图书馆市场（依分销管道）

  • 直销（B2B供应）
  • 合约/外包服务
  • 线上平台

9. 全球DNA编码图书馆市场（按应用）

  • 药物研发
  • 目标识别和检验

10. 全球 DNA 编码图书馆市场（依最终用户划分）

  • 製药公司
  • 生技公司
  • 合约研究组织

11. 全球 DNA 编码图书馆市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十二章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十三章：企业概况

  • X-Chem
  • HitGen
  • Nuevolution（Amgen）
  • Vipergen
  • GSK
  • Merck KGaA
  • WuXi AppTec
  • GenScript
  • Pharmaron
  • Aurigene Pharmaceutical Services
  • BOC Sciences
  • LGC Bioresearch Technologies
  • SPT Labtech Ltd.
  • Life Chemicals
  • Charles River Laboratories
  • DyNAbind
  • ComInnex
Product Code: SMRC30733

According to Stratistics MRC, the Global DNA Encoded Library Market is accounted for $3.5 billion in 2025 and is expected to reach $6.7 billion by 2032 growing at a CAGR of 9.8% during the forecast period. DNA Encoded Libraries are collections of small molecules chemically linked to unique DNA sequences that act as barcodes, enabling rapid identification of compounds with biological activity. Used in drug discovery, they allow high-throughput screening of millions to billions of compounds against target proteins. DNA tags enable efficient selection, amplification, and sequencing of potential drug candidates. This technology combines chemistry and molecular biology, streamlining early-stage pharmaceutical research and significantly accelerating the identification of promising leads.

According to the World Health Organization (WHO), with a growing share being allocated to innovative drug discovery technologies like DECLs. Pharmaceutical companies are seeking to diversify their pipelines and identify novel compounds for unmet medical needs, particularly in cancer, neurological diseases, and rare genetic disorders, where DECLs are particularly promising.

Market Dynamics:

Driver:

Increasing investments in pharmaceutical R&D

The DNA encoded library market is driven by escalating investments in pharmaceutical research and development aimed at accelerating drug discovery. Pharmaceutical companies and research institutes are channeling significant funds into advanced screening technologies to identify novel drug candidates efficiently. DEL platforms enable rapid testing of billions of compounds, reducing cost and time in preclinical phases. Fueled by rising chronic disease prevalence and demand for precision medicine, pharmaceutical R&D expansion continues to be a primary catalyst for market adoption globally.

Restraint:

Limited expertise in library design processes

A major restraint hindering the DNA encoded library market is the shortage of expertise in designing and synthesizing complex molecular libraries. DEL requires advanced technical proficiency and specialized knowledge in chemistry, molecular biology, and bioinformatics. Many pharmaceutical firms and academic institutions face challenges in establishing in-house capabilities, slowing wider adoption. Outsourcing to specialized CROs partly mitigates this gap, but dependency on external expertise often raises costs and limits scalability. Consequently, limited design expertise restricts rapid expansion of DEL platforms globally.

Opportunity:

Collaborations between biotech and pharma companies

A promising opportunity lies in strategic collaborations between biotechnology firms and large pharmaceutical players to enhance DNA encoded library platforms. Partnerships allow pooling of resources, technical expertise, and compound collections, enabling accelerated identification of novel therapeutic molecules. Such alliances foster cross-industry innovation and de-risk R&D pipelines by sharing costs. Increasingly, biotech startups are leveraging DEL platforms to co-develop targeted drugs, supported by pharma's distribution capabilities. This collaborative ecosystem strengthens innovation pipelines and opens lucrative opportunities in therapeutic development.

Threat:

Ethical concerns regarding genetic data usage

The DNA encoded library market faces potential threats from ethical concerns linked to the use of genetic data in research. While DEL focuses on drug discovery, it often intersects with genomic datasets that raise privacy and consent-related issues. Misuse or unauthorized access to sensitive biological information could undermine trust among stakeholders. Additionally, stringent data protection regulations across regions add compliance challenges for companies. Ethical scrutiny around genetic data usage remains a significant barrier that may hinder long-term adoption.

Covid-19 Impact:

The COVID-19 pandemic reshaped priorities in drug discovery, accelerating adoption of DNA encoded libraries for rapid therapeutic screening. DEL platforms enabled high-throughput screening of compounds against SARS-CoV-2 targets, contributing to antiviral research. However, supply chain disruptions temporarily impacted synthesis workflows and laboratory collaborations. Post-pandemic, renewed focus on preparedness against infectious diseases has reinforced the importance of scalable drug discovery methods. As pharmaceutical pipelines broaden beyond COVID-19, DEL platforms are positioned as vital tools supporting speed and efficiency in R&D.

The DNA oligonucleotides segment is expected to be the largest during the forecast period

The DNA oligonucleotides segment is expected to account for the largest market share during the forecast period, propelled by their essential role in constructing and encoding vast molecular libraries. DNA oligos act as barcodes, enabling identification of binding interactions at scale. Their versatility in high-throughput screening and expanding applications across oncology, immunology, and infectious disease research boost demand. With continuous advancements in synthesis techniques, DNA oligonucleotides are becoming more cost-efficient, further strengthening their dominant position in the DEL market landscape.

The library design & synthesis segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the library design & synthesis segment is predicted to witness the highest growth rate, influenced by the increasing demand for customized compound libraries tailored to specific therapeutic targets. Advanced computational tools and AI-driven approaches are enabling precise design of large-scale libraries. Pharmaceutical companies are seeking high-quality, diverse compound sets to improve hit identification. As collaborations between CROs and pharma expand, investment in sophisticated library design workflows is accelerating, making this the fastest-growing segment in the market.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, fueled by expanding pharmaceutical R&D hubs, rising government investments in biotechnology, and cost-efficient clinical trials. Countries like China, India, and Japan are actively adopting DEL platforms to accelerate new drug discovery. Strong academic-industry partnerships, availability of skilled researchers, and growing demand for affordable therapeutics strengthen regional growth. The region's ability to combine scale, cost advantages, and increasing innovation drives its leadership position in the DEL market.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, driven by strong pharmaceutical infrastructure, advanced technological adoption, and high research funding. The U.S. remains a key hub for DEL innovation, supported by leading pharma giants, biotech startups, and academic institutions. Ongoing collaborations with CROs and rising investment in precision medicine further fuel growth. Robust regulatory support and an established healthcare ecosystem create fertile ground for rapid expansion, positioning North America as the fastest-growing region.

Key players in the market

Some of the key players in DNA Encoded Library Market include X-Chem, HitGen, Nuevolution, Vipergen, GSK, Merck KGaA, WuXi AppTec, GenScript, Pharmaron, Aurigene Discovery Technologies Ltd., BOC Sciences, LGC Bioresearch Technologies, SPT Labtech, Life Chemicals, Charles River Laboratories, DyNAbind GmbH, and Cominmex.

Key Developments:

In August 2025, X-Chem significantly expanded its DNA encoded library platform by introducing a new high-capacity library. This advancement facilitates accelerated drug discovery, enabling researchers to target a wider and more diverse array of protein classes with improved efficiency and precision.

In July 2025, HitGen announced a strategic collaboration with several pharmaceutical partners aimed at leveraging its DNA encoded library technology to identify targets for cancer immunotherapy. This collaboration is expected to enhance the company's capabilities in developing innovative cancer treatments.

In June 2025, Nuevolution launched an enhanced DNA encoded library (DEL) screening platform that integrates advanced AI-driven analytics. This platform improves the accuracy and speed of hit identification, accelerating the drug discovery process by enabling more efficient analysis of large data sets.

Materials Covered:

  • DNA Oligonucleotides
  • Chemical Linkers
  • Synthetic Building Blocks

Workflows Covered:

  • Library Screening & Analysis
  • Library Design & Synthesis

Technologies Covered:

  • DNA-Directed Synthesis (DDS)
  • DNA-Recorded Synthesis
  • DNA-Templated Synthesis
  • DNA-Tagged Affinity Selection
  • Other Technologies

Distribution Channels Covered:

  • Direct Sales (B2B Supply)
  • Contract/Outsourced Services
  • Online Platforms

Applications Covered:

  • Drug Discovery & Development
  • Target Identification & Validation

End Users Covered:

  • Pharmaceutical Companies
  • Biotechnology Firms
  • Contract Research Organizations

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global DNA Encoded Library Market, By Material

  • 5.1 Introduction
  • 5.2 DNA Oligonucleotides
  • 5.3 Chemical Linkers
  • 5.4 Synthetic Building Blocks

6 Global DNA Encoded Library Market, By Workflow

  • 6.1 Introduction
  • 6.2 Library Screening & Analysis
  • 6.3 Library Design & Synthesis

7 Global DNA Encoded Library Market, By Technology

  • 7.1 Introduction
  • 7.2 DNA-Directed Synthesis (DDS)
  • 7.3 DNA-Recorded Synthesis
  • 7.4 DNA-Templated Synthesis
  • 7.5 DNA-Tagged Affinity Selection
  • 7.6 Other Technologies

8 Global DNA Encoded Library Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Direct Sales (B2B Supply)
  • 8.3 Contract/Outsourced Services
  • 8.4 Online Platforms

9 Global DNA Encoded Library Market, By Application

  • 9.1 Introduction
  • 9.2 Drug Discovery & Development
  • 9.3 Target Identification & Validation

10 Global DNA Encoded Library Market, By End User

  • 10.1 Introduction
  • 10.2 Pharmaceutical Companies
  • 10.3 Biotechnology Firms
  • 10.4 Contract Research Organizations

11 Global DNA Encoded Library Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 X-Chem
  • 13.2 HitGen
  • 13.3 Nuevolution (Amgen)
  • 13.4 Vipergen
  • 13.5 GSK
  • 13.6 Merck KGaA
  • 13.7 WuXi AppTec
  • 13.8 GenScript
  • 13.9 Pharmaron
  • 13.10 Aurigene Pharmaceutical Services
  • 13.11 BOC Sciences
  • 13.12 LGC Bioresearch Technologies
  • 13.13 SPT Labtech Ltd.
  • 13.14 Life Chemicals
  • 13.15 Charles River Laboratories
  • 13.16 DyNAbind
  • 13.17 ComInnex

List of Tables

  • Table 1 Global DNA Encoded Library Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global DNA Encoded Library Market Outlook, By Material (2024-2032) ($MN)
  • Table 3 Global DNA Encoded Library Market Outlook, By DNA Oligonucleotides (2024-2032) ($MN)
  • Table 4 Global DNA Encoded Library Market Outlook, By Chemical Linkers (2024-2032) ($MN)
  • Table 5 Global DNA Encoded Library Market Outlook, By Synthetic Building Blocks (2024-2032) ($MN)
  • Table 6 Global DNA Encoded Library Market Outlook, By Workflow (2024-2032) ($MN)
  • Table 7 Global DNA Encoded Library Market Outlook, By Library Screening & Analysis (2024-2032) ($MN)
  • Table 8 Global DNA Encoded Library Market Outlook, By Library Design & Synthesis (2024-2032) ($MN)
  • Table 9 Global DNA Encoded Library Market Outlook, By Technology (2024-2032) ($MN)
  • Table 10 Global DNA Encoded Library Market Outlook, By DNA-Directed Synthesis (DDS) (2024-2032) ($MN)
  • Table 11 Global DNA Encoded Library Market Outlook, By DNA-Recorded Synthesis (2024-2032) ($MN)
  • Table 12 Global DNA Encoded Library Market Outlook, By DNA-Templated Synthesis (2024-2032) ($MN)
  • Table 13 Global DNA Encoded Library Market Outlook, By DNA-Tagged Affinity Selection (2024-2032) ($MN)
  • Table 14 Global DNA Encoded Library Market Outlook, By Other Technologies (2024-2032) ($MN)
  • Table 15 Global DNA Encoded Library Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 16 Global DNA Encoded Library Market Outlook, By Direct Sales (B2B Supply) (2024-2032) ($MN)
  • Table 17 Global DNA Encoded Library Market Outlook, By Contract/Outsourced Services (2024-2032) ($MN)
  • Table 18 Global DNA Encoded Library Market Outlook, By Online Platforms (2024-2032) ($MN)
  • Table 19 Global DNA Encoded Library Market Outlook, By Application (2024-2032) ($MN)
  • Table 20 Global DNA Encoded Library Market Outlook, By Drug Discovery & Development (2024-2032) ($MN)
  • Table 21 Global DNA Encoded Library Market Outlook, By Target Identification & Validation (2024-2032) ($MN)
  • Table 22 Global DNA Encoded Library Market Outlook, By End User (2024-2032) ($MN)
  • Table 23 Global DNA Encoded Library Market Outlook, By Pharmaceutical Companies (2024-2032) ($MN)
  • Table 24 Global DNA Encoded Library Market Outlook, By Biotechnology Firms (2024-2032) ($MN)
  • Table 25 Global DNA Encoded Library Market Outlook, By Contract Research Organizations (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.